Sansure Biotech Inc. (SHA:688289)
16.08
+0.18 (1.13%)
Sep 14, 2026, 3:00 PM CST
Sansure Biotech Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,607 | 1,642 | 1,458 | 1,007 | 6,450 | 4,515 |
Revenue Growth | -0.15% | 12.58% | 44.78% | -84.39% | 42.88% | -5.22% |
Gross Profit Gross Profit Growth | 1,180 | 1,221 | 1,178 | 726.15 | 3,538 | 3,232 |
Operating Income Operating Income Growth | 50.65 | 133.85 | 127.26 | -21.08 | 2,194 | 2,526 |
Net Income Net Income Growth | 134.24 | 198.94 | 275.6 | 363.72 | 1,937 | 2,243 |
Earnings Per Share EPS Growth | 0.23 | 0.34 | 0.47 | 0.62 | 3.31 | 3.81 |
EPS Growth | -52.01% | -27.66% | -24.19% | -81.27% | -13.12% | -19.56% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
China China Growth | 1,533 |
Overseas Overseas Growth | 83.08 |
Total Total Growth | 1,616 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 3,821 | 4,125 | 4,730 | 4,782 | 5,664 | 4,683 |
Total Debt Total Debt Growth | 1,525 | 1,127 | 422.85 | 38.31 | 27.86 | 14.9 |
Net Cash (Debt) Net Cash Growth | 2,296 | 2,998 | 4,307 | 4,743 | 5,636 | 4,668 |
Net Cash Growth | -25.99% | -30.39% | -9.20% | -15.83% | 20.74% | 12.83% |
Net Cash Per Share Net Cash Per Share Growth | 3.94 | 5.12 | 7.35 | 8.09 | 9.63 | 7.93 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 311.15 | 183.96 | 274.45 | 43.54 | 2,559 | 1,877 |
Capital Expenditures CapEx Growth | -369.68 | -369.77 | -421.1 | -391.35 | -558.83 | -372.86 |
Free Cash Flow Free Cash Flow Growth | -58.53 | -185.81 | -146.66 | -347.81 | 2,000 | 1,504 |
Free Cash Flow Growth | - | - | - | - | 32.97% | -40.63% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 73.41% | 74.40% | 80.82% | 72.10% | 54.85% | 71.58% |
Operating Margin | 3.15% | 8.15% | 8.73% | -2.09% | 34.01% | 55.94% |
Pretax Margin | 6.24% | 10.67% | 17.87% | 40.76% | 35.90% | 57.95% |
Profit Margin | 8.35% | 12.12% | 18.90% | 36.12% | 30.03% | 49.68% |
FCF Margin | -3.64% | -11.32% | -10.06% | -34.53% | 31.01% | 33.32% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.523 | 0.523 | 0.525 | 0.462 | 1.298 | 0.760 |
Dividend Per Share Growth | -0.38% | -0.38% | 13.59% | -64.39% | 70.77% | 0% |
Dividend Yield | 3.31% | 2.82% | 2.42% | 2.54% | 6.59% | 2.22% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 69.04 | 54.58 | 47.17 | 30.76 | 6.58 | 10.52 |
Forward PE | 36.41 | 26.22 | 35.75 | 51.11 | 8.19 | 12.20 |
P/FCF Ratio | - | - | - | - | 6.37 | 15.69 |
PS Ratio | 5.69 | 6.61 | 8.92 | 11.11 | 1.98 | 5.23 |